Table 4.

Outcomes of 14 patients with AE-ILD after chemotherapy

	No.	Treatment line	Associated regimens	Onset of AE (days from chemotherapy)	Outcome	Survival time (days from onset of AE)
Non-Bev group	1	First	CDDP + PEM	79	Recover	125
	2	First	CBDCA + PEM	110	Dead	87
	3	First	CBDCA + PEM	5	Recovered	125
	4	First	CBDCA + PEM	59	Dead	77
	5	First	CBDCA + PEM	45	Dead	11
	6	First	CBDCA + PEM	54	Recovered	626
	7	First	CBDCA + PTX	87	Dead	36
	8	Second	DOC	169	Recovered	276
	9	Second	DOC	193	Recovered	522
	10	Second	S-1	120	Dead	5
	11	Second	DOC	426	Dead	4
	12	Third	DOC	372	Dead	67
Bev group	13	Second	nab-PTX	156	Dead	34
	14	Third	DOC	386	Dead	17

AE acute exacerbation, Bev bevacizumab, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel, DOC docetaxel, nab-PTX nab-paclitaxel, VNR vinorelbine